http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 06:45:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html <p>Merck Animal Health, a division of Merck & Co. (NYSE: MRK), signed a definitive agreement to acquire TARGAN, a privately held company that develops biodevice solutions for the poultry industry. The purchase price was not disclosed.</p> <p>The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Merck Animal Health has been an investor in TARGAN since 2017 and holds one of the company's largest ownership stakes.</p> <p>TARGAN, founded in 2015 and based in Raleigh, North Carolina, develops automated solutions for commercial hatcheries. The company's WingScan technology uses vision technology to identify and http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html Thu, 11 Jun 2026 06:45:23 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html <p>Merck Animal Health, a division of Merck & Co. (NYSE: MRK), signed a definitive agreement to acquire TARGAN, a privately held company that develops biodevice solutions for the poultry industry. The purchase price was not disclosed.</p> <p>The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Merck Animal Health has been an investor in TARGAN since 2017 and holds one of the company's largest ownership stakes.</p> <p>TARGAN, founded in 2015 and based in Raleigh, North Carolina, develops automated solutions for commercial hatcheries. The company's WingScan technology uses vision technology to identify and http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html Thu, 11 Jun 2026 06:45:23 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html <p>Merck Animal Health, a division of Merck & Co. (NYSE: MRK), signed a definitive agreement to acquire TARGAN, a privately held company that develops biodevice solutions for the poultry industry. The purchase price was not disclosed.</p> <p>The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Merck Animal Health has been an investor in TARGAN since 2017 and holds one of the company's largest ownership stakes.</p> <p>TARGAN, founded in 2015 and based in Raleigh, North Carolina, develops automated solutions for commercial hatcheries. The company's WingScan technology uses vision technology to identify and http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html Thu, 11 Jun 2026 06:45:23 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html <p>Merck Animal Health, a division of Merck & Co. (NYSE: MRK), signed a definitive agreement to acquire TARGAN, a privately held company that develops biodevice solutions for the poultry industry. The purchase price was not disclosed.</p> <p>The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Merck Animal Health has been an investor in TARGAN since 2017 and holds one of the company's largest ownership stakes.</p> <p>TARGAN, founded in 2015 and based in Raleigh, North Carolina, develops automated solutions for commercial hatcheries. The company's WingScan technology uses vision technology to identify and http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html Thu, 11 Jun 2026 06:45:23 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html <p>Merck Animal Health, a division of Merck & Co. (NYSE: MRK), signed a definitive agreement to acquire TARGAN, a privately held company that develops biodevice solutions for the poultry industry. The purchase price was not disclosed.</p> <p>The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Merck Animal Health has been an investor in TARGAN since 2017 and holds one of the company's largest ownership stakes.</p> <p>TARGAN, founded in 2015 and based in Raleigh, North Carolina, develops automated solutions for commercial hatcheries. The company's WingScan technology uses vision technology to identify and http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html Thu, 11 Jun 2026 06:45:23 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html <p>Merck Animal Health, a division of Merck & Co. (NYSE: MRK), signed a definitive agreement to acquire TARGAN, a privately held company that develops biodevice solutions for the poultry industry. The purchase price was not disclosed.</p> <p>The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary closing conditions. Merck Animal Health has been an investor in TARGAN since 2017 and holds one of the company's largest ownership stakes.</p> <p>TARGAN, founded in 2015 and based in Raleigh, North Carolina, develops automated solutions for commercial hatcheries. The company's WingScan technology uses vision technology to identify and http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+Animal+Health+to+acquire+poultry+technology+firm+TARGAN/26632298.html Thu, 11 Jun 2026 06:45:23 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Press+Releases/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html <p class="bwalignc"> <b>TARGAN’s innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance</b> </p> <p> RAHWAY, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company’s largest shareholders. </p><p> The http://www.streetinsider.com/Business+Wire/Merck+Animal+Health+to+Acquire+TARGAN/26632295.html Thu, 11 Jun 2026 06:45:00 -0400 A.50201041 A.60001746 MRK O.00037438 O.00832581 O.52477530 http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html <p>Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co. Inc. (NYSE: MRK) reported that their investigational once-weekly oral HIV treatment regimen of islatravir/lenacapavir met primary efficacy endpoints at Week 48 in two Phase 3 trials, according to a press release statement.</p> <p>The ISLEND-1 and ISLEND-2 trials evaluated the combination of islatravir 2 mg and lenacapavir 300 mg in people with HIV who were virologically suppressed. The treatment demonstrated statistical non-inferiority to existing regimens, with ISLEND-1 comparing against BIKTARVY and ISLEND-2 against standard of care antiretroviral regimens.</p> <p>The primary efficacy endpoint measured the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html Mon, 08 Jun 2026 16:35:26 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html <p>Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co. Inc. (NYSE: MRK) reported that their investigational once-weekly oral HIV treatment regimen of islatravir/lenacapavir met primary efficacy endpoints at Week 48 in two Phase 3 trials, according to a press release statement.</p> <p>The ISLEND-1 and ISLEND-2 trials evaluated the combination of islatravir 2 mg and lenacapavir 300 mg in people with HIV who were virologically suppressed. The treatment demonstrated statistical non-inferiority to existing regimens, with ISLEND-1 comparing against BIKTARVY and ISLEND-2 against standard of care antiretroviral regimens.</p> <p>The primary efficacy endpoint measured the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html Mon, 08 Jun 2026 16:35:26 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html <p>Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co. Inc. (NYSE: MRK) reported that their investigational once-weekly oral HIV treatment regimen of islatravir/lenacapavir met primary efficacy endpoints at Week 48 in two Phase 3 trials, according to a press release statement.</p> <p>The ISLEND-1 and ISLEND-2 trials evaluated the combination of islatravir 2 mg and lenacapavir 300 mg in people with HIV who were virologically suppressed. The treatment demonstrated statistical non-inferiority to existing regimens, with ISLEND-1 comparing against BIKTARVY and ISLEND-2 against standard of care antiretroviral regimens.</p> <p>The primary efficacy endpoint measured the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html Mon, 08 Jun 2026 16:35:26 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html <p>Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co. Inc. (NYSE: MRK) reported that their investigational once-weekly oral HIV treatment regimen of islatravir/lenacapavir met primary efficacy endpoints at Week 48 in two Phase 3 trials, according to a press release statement.</p> <p>The ISLEND-1 and ISLEND-2 trials evaluated the combination of islatravir 2 mg and lenacapavir 300 mg in people with HIV who were virologically suppressed. The treatment demonstrated statistical non-inferiority to existing regimens, with ISLEND-1 comparing against BIKTARVY and ISLEND-2 against standard of care antiretroviral regimens.</p> <p>The primary efficacy endpoint measured the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html Mon, 08 Jun 2026 16:35:26 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html <p>Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co. Inc. (NYSE: MRK) reported that their investigational once-weekly oral HIV treatment regimen of islatravir/lenacapavir met primary efficacy endpoints at Week 48 in two Phase 3 trials, according to a press release statement.</p> <p>The ISLEND-1 and ISLEND-2 trials evaluated the combination of islatravir 2 mg and lenacapavir 300 mg in people with HIV who were virologically suppressed. The treatment demonstrated statistical non-inferiority to existing regimens, with ISLEND-1 comparing against BIKTARVY and ISLEND-2 against standard of care antiretroviral regimens.</p> <p>The primary efficacy endpoint measured the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html Mon, 08 Jun 2026 16:35:26 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html <p>Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co. Inc. (NYSE: MRK) reported that their investigational once-weekly oral HIV treatment regimen of islatravir/lenacapavir met primary efficacy endpoints at Week 48 in two Phase 3 trials, according to a press release statement.</p> <p>The ISLEND-1 and ISLEND-2 trials evaluated the combination of islatravir 2 mg and lenacapavir 300 mg in people with HIV who were virologically suppressed. The treatment demonstrated statistical non-inferiority to existing regimens, with ISLEND-1 comparing against BIKTARVY and ISLEND-2 against standard of care antiretroviral regimens.</p> <p>The primary efficacy endpoint measured the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL http://www.streetinsider.com/FDA/Gilead+and+Merck+announce+successful+HIV+treatment+trial+results/26617904.html Mon, 08 Jun 2026 16:35:26 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344 http://www.streetinsider.com/Press+Releases/Gilead+and+Merck+Announce+Positive+Topline+Results+From+Two+Phase+3+Studies+Evaluating+IslatravirLenacapavir%2C+an+Oral+Once-Weekly+HIV+Treatment/26617892.html <p class="bwalignc"> <b><i>– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle –</i></b> </p><p class="bwalignc"> <b><i>– Islatravir/Lenacapavir has the Potential to be the First Approved Long-Acting Oral HIV Treatment Taken Once-Weekly –</i></b> </p> <p> FOSTER CITY, Calif., &amp; RAHWAY, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase http://www.streetinsider.com/Press+Releases/Gilead+and+Merck+Announce+Positive+Topline+Results+From+Two+Phase+3+Studies+Evaluating+IslatravirLenacapavir%2C+an+Oral+Once-Weekly+HIV+Treatment/26617892.html Mon, 08 Jun 2026 16:35:00 -0400 A.06822034 GILD MRK O.00037438 O.00092067 O.20026344